Abstract: The invention features compositions and methods that are useful for increasing the level or activity of SLC16A11 in a subject, there by treating or preventing type 2 diabetes in the subject.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
October 18, 2022
Assignees:
THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Eitan Hoch, Suzanne Beth Rosenberg Jacobs, Victor Rusu, Liping Zhao, Jose M. Mercader Bigas
Abstract: Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Type:
Grant
Filed:
May 4, 2022
Date of Patent:
October 4, 2022
Assignee:
NeuroDerm, Ltd.
Inventors:
Tal Birnberg, Liat Adar, Itay Perlstein
Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.
Type:
Grant
Filed:
April 19, 2019
Date of Patent:
September 27, 2022
Assignee:
Estetra SPRL
Inventors:
Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
September 27, 2022
Assignee:
EIRGEN PHARMA LTD.
Inventors:
Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.
Type:
Grant
Filed:
August 20, 2020
Date of Patent:
September 27, 2022
Assignee:
TURNING POINT THERAPEUTICS, INC.
Inventors:
Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Zhongdong Huang
Abstract: Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: Methods and products are provided for preventing or reducing adverse effects of air travel, jet lag, and shift switching. Doses of antioxidant, anti-inflammatory, mitochondrial support, circadian shift support, and/or other agents are administered to or by the subject at selected times, and the subject sleeps or refrains from sleep, and/or is exposed to or protected from light, for selected times.
Abstract: A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect.
Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Type:
Grant
Filed:
July 28, 2015
Date of Patent:
August 16, 2022
Assignees:
The Regents of the University of California, Meritage Pharma, Inc.
Inventors:
Ranjan Dohil, John Bastian, Seema S. Aceves, Elaine Phillips, Malcolm Hill
Abstract: Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
Type:
Grant
Filed:
August 27, 2021
Date of Patent:
August 9, 2022
Assignee:
SMALL PHARMA LTD
Inventors:
Marie Claire Layzell, James Maxwell Rennie
Abstract: The preparation, composition, and method of use of an antibacterial formulation utilizing tannins, acceptable for agriculture and for use against bacterial and fungicidal diseases in plants. The composition is based on an organic matrix and may be balanced with dispersants, flocculants and humectants, and may be used against a wide range of agricultural bacterial diseases.
Type:
Grant
Filed:
January 21, 2022
Date of Patent:
August 9, 2022
Assignee:
QUIMICA AGRONOMICA DE MEXICO S. DE R.L. DE C.V.
Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.
Abstract: Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
July 19, 2022
Assignee:
Palo Alto Investors
Inventors:
Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.
Abstract: Provided herein are oral drug preparations including cyproterone acetate and ethinylestradiol, dosing regimen for the drug preparations, and methods of treating diseases. The methods provided include the administration of the oral drug preparation to treat one or more symptoms of hyperandrogenic conditions or hyperandrogenic activities, to provide contraception, and to reduce a risk of vascular thromboembolism (VTE) in a subject.
Abstract: A 10-formyl-THF pathway for producing NADPH is useful in the diagnosis and treatment of cancer and metabolic disease, in the development of new antineoplastic agents and/or regimens, in the development of new methods for measuring metabolic pathway activity, and in the development of new therapeutics for treating metabolic disease.
Type:
Grant
Filed:
September 15, 2016
Date of Patent:
June 28, 2022
Assignee:
The Trustees of Princeton University
Inventors:
Joshua D. Rabinowitz, Jing Fan, Gregory S. Ducker